Basic Research
Copyright ©The Author(s) 2004.
World J Gastroenterol. Aug 15, 2004; 10(16): 2344-2351
Published online Aug 15, 2004. doi: 10.3748/wjg.v10.i16.2344
Figure 6
Figure 6 PSCs were treated with HNE (at 0, 1, or 5 μmol/L ) in the absence or presence of PDGF (at 25 ng/mL) in serum-free medium. After 24-h incubation, cells were labeled with BrdU for 3 h. Cells were fixed, and incubated with peroxidase-conju-gated anti-BrdU antibody. Then the peroxidase substrate 3,3’, 5,5’-tetramethylbenzidine was added, and BrdU incorporation was quantitated by differences in absorbance at wavelength 370 min 492 nm (“A.”, optical density). Data are shown as mean ± SD (n = 6). bP < 0.01 versus control (serum-free medium only), N.S.: not significant.